Structural differences in antibody binding orientations to HRV14 correlate with their ability to neutralize viral infectivity.
No takes yet. Share an insight, caveat, or question.
Antibody orientation may predict neutralization potency; leaves open translation to human rhinovirus therapies.
Che et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: